Evidence map›Paper›PMID 38886818›Full record

ArticleBreast cancer research : BCR2024

Association of early menarche with breast tumor molecular features and recurrence.

Alexandra R Harris, Tengteng Wang, Yujing J Heng, Gabrielle M Baker, Phuong Anh Le, Jun Wang, Christine Ambrosone, Adam Brufsky, Fergus J Couch, Francesmary Modugno and 7 more

Abstract read
In one paragraph

Article in Breast cancer research : BCR, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Inflammatory factors collaboratively linkFrontiers in immunology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Alexandra R HarrisChanning Division of Network Medicine, Brigham and Women's Hospital, Boston, MA, USA. alexandra.harris2@nih.gov.
Tengteng WangChanning Division of Network Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Yujing J HengDepartment of Pathology, Harvard Medical School, Boston, MA, USA.
Gabrielle M BakerDepartment of Pathology, Harvard Medical School, Boston, MA, USA.
Phuong Anh LeDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Jun WangDepartment of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Christine AmbrosoneDepartment of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Adam BrufskyDepartment of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PN, USA.
Fergus J CouchDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Francesmary ModugnoDivision of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Christopher G ScottDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
Celine M VachonDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
Susan E HankinsonChanning Division of Network Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Bernard A RosnerChanning Division of Network Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Rulla M TamimiDepartment of Population Health Sciences, Weill Cornell Medical College, New York, NY, USA.
Cheng Peng *Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, MA, USA.
A Heather Eliassen *Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, MA, USA.

Funding

Two-Spirit Films in Indigenous Cancer HealthP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI MARK G FRATTINI · 1985 to 2026
$116.6M
Statistical MethodsP01CA087969 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI ROSNER, BERNARD A · 2000 to 2019
$77.8M
The Role of CHFR in Tumorigenesis and Paclitaxel-Sensitivity in Breast CancerP50CA116201 · NCI · MAYO CLINIC ROCHESTER · PI PETER C LUCAS · 2005 to 2026
$49.9M
Risk Factors for Breast Cancer in Younger NursesR01CA050385 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI ELIASSEN, A. HEATHER, WILLETT, WALTER C. · 1989 to 2019
$32.3M
Life Course Cancer Epidemiology Cohort in WomenU01CA176726 · NCI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI ELIASSEN, A. HEATHER, WILLETT, WALTER C. · 2018 to 2025
$22.4M
Long Term Multidisciplinary Study of Cancer in Women: The Nurses Health StudyUM1CA186107 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI ELIASSEN, A. HEATHER, STAMPFER, MEIR · 2014 to 2023
$22.3M
Training Program in Cancer EpidemiologyT32CA009001 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI A. Heather Eliassen, Meir Stampfer · 1985 to 2026
$17.3M
Premonopausal Hormone Levels and Risk of Breast CancerR01CA067262 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI HANKINSON, SUSAN E · 2002 to 2011
$11.9M
BIOCHEMICAL MARKERS IN THE NURSES'HEALTH STUDY COHORTR01CA049449 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI HANKINSON, SUSAN E · 1989 to 2008
$11.3M
Epidemiologic StudiesU19CA148065 · NCI · HARVARD SCHOOL OF PUBLIC HEALTH · PI AHSAN, HABIBUL, BRUGGE, JOAN SIEFERT · 2010 to 2014
$10.6M
Resolving the cancer relevance of predisposition gene mutationsR35CA253187 · NCI · MAYO CLINIC ROCHESTER · PI Fergus Joseph Couch · 2020 to 2026
$5.8M
Assessing the role of androgens in breast cancer riskR01CA166666 · NCI · UNIVERSITY OF MASSACHUSETTS AMHERST · PI HANKINSON, SUSAN E · 2012 to 2015
$1.7M
NCI NIH HHS P01 CA087969NCI NIH HHS P30 CA016056NCI NIH HHS P50 CA116201NCI NIH HHS R01 CA049449NCI NIH HHS R01 CA050385NCI NIH HHS R01 CA067262NCI NIH HHS R01 CA166666NCI NIH HHS R35 CA253187NCI NIH HHS T32 CA009001NCI NIH HHS U01 CA176726NCI NIH HHS U19 CA148065NCI NIH HHS UM1 CA186107NIA NIH HHS K01 AG080030NIA NIH HHS K01AG080030NIH HHS UM1 CA186107, P01 CA87969, R01 CA49449, U01 CA176726, R01 CA67262, R01 CA50385, T32 CA009001, U19 CA148065, R01 CA166666, P30 CA016056, R35 CA253187, P50 CA116201Susan G. Komen SAC110014
6 · The paper itself

Abstract

backgroundEarly menarche is an established risk factor for breast cancer but its molecular contribution to tumor biology and prognosis remains unclear.

methodsWe profiled transcriptome-wide gene expression in breast tumors (N = 846) and tumor-adjacent normal tissues (N = 666) from women in the Nurses' Health Studies (NHS) to investigate whether early menarche (age < 12) is associated with tumor molecular and prognostic features in women with breast cancer. Multivariable linear regression and pathway analyses using competitive gene set enrichment analysis were conducted in both tumor and adjacent-normal tissue and externally validated in TCGA (N = 116). Subgroup analyses stratified on ER-status based on the tumor were also performed. PAM50 signatures were used for tumor molecular subtyping and to generate proliferation and risk of recurrence scores. We created a gene expression score using LASSO regression to capture early menarche based on 28 genes from FDR-significant pathways in breast tumor tissue in NHS and tested its association with 10-year disease-free survival in both NHS (N = 836) and METABRIC (N = 952).

resultsEarly menarche was significantly associated with 369 individual genes in adjacent-normal tissues implicated in extracellular matrix, cell adhesion, and invasion (FDR ≤ 0.1). Early menarche was associated with upregulation of cancer hallmark pathways (18 significant pathways in tumor, 23 in tumor-adjacent normal, FDR ≤ 0.1) related to proliferation (e.g. Myc, PI3K/AKT/mTOR, cell cycle), oxidative stress (e.g. oxidative phosphorylation, unfolded protein response), and inflammation (e.g. pro-inflammatory cytokines IFN

conclusionsEarly menarche is associated with more aggressive molecular tumor characteristics and its gene expression signature within tumors is associated with worse 10-year disease-free survival among women with breast cancer. As the age of onset of menarche continues to decline, understanding its relationship to breast tumor characteristics and prognosis may lead to novel secondary prevention strategies.

Indexed as

Breast NeoplasmsGene Expression ProfilingMenarcheNeoplasm Recurrence, LocalTranscriptomeAdultAge FactorsBiomarkers, TumorFemaleGene Expression Regulation, NeoplasticHumansMiddle AgedPrognosisRisk FactorsBiomarkers, TumorAge at menarcheBreast cancer recurrenceEarly-life risk factors of breast tumor biologyEarly menarche gene expression signatureReproductive risk factors of breast cancer

Identifiers

PMID38886818
PMCPMC11181557

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.